Nasus Pharma (NSRX) Gains from Investment Securities (2024 - 2025)
Nasus Pharma (NSRX) reported Gains from Investment Securities of $810571.0 for Q4 2025, up 322.83% on a YoY basis from $191700.0 in Q4 2024, and up 322.83% quarter-over-quarter from $191700.0 in Q4 2024.
Nasus Pharma (NSRX) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Gains from Investment Securities for 2 years, with the latest figure at $810571.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities rose 322.83% year-over-year to $810571.0; the trailing twelve-month figure through Dec 2025 stood at $810571.0 (up 322.83% YoY), and the FY2025 full-year result was $810571.0, up 322.83% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $810571.0, up from $191700.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $810571.0 in Q4 2025, with the low at $191700.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 810,571.00 |
| Dec 31, 2025 | 810,571.00 |
| Dec 31, 2024 | 191,700.00 |
| Dec 31, 2024 | 191,700.00 |